Similarly, in autoimmune and allergic diseases that are CD4+ T cell–dependent, T-helper polarization, or in MHC class II–restricted diseases, SDHA inhibition could mitigate autoimmune/allergic disorders. This evidence concerns the gene HLA-C and allergic disease.